Ticker Details
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Inc is engaged in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases in specialty markets. Its products include SYMDEKO, ORKAMBI, and KALYDECO.
IPO Date:	July 24, 1991
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$113.64B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$1.89 | 1.66%
Avg Daily Range (30 D):	$6.88 | 1.48%
Avg Daily Range (90 D):	$6.21 | 1.35%

Institutional Daily Volume
Avg Daily Volume:	1.58M
Avg Daily Volume (30 D):	1.03M
Avg Daily Volume (90 D):	1.04M

Trade Size
Avg Trade Size (Sh.):	90
Avg Trade Size (Sh.) (30 D):	25
Avg Trade Size (Sh.) (90 D):	26

Institutional Trades
Total Institutional Trades:	30,599
Avg Institutional Trade:	$8.96M
Avg Institutional Trade (30 D):	$33.02M
Avg Institutional Trade (90 D):	$39.57M
Avg Institutional Trade Volume:	.05M
Avg Institutional Trades (Per Day):	5

Market Closing Trades
Avg Closing Trade:	$33.25M
Avg Closing Trade (30 D):	$128.27M
Avg Closing Trade (90 D):	$121.89M
Avg Closing Volume:	147.56K

News

Apr 10, 2026 @ 1:55 PM Biotechs Racing to Translate Longevity Science Int... Source: Usa News Group

Apr 7, 2026 @ 5:44 PM Global DNA Read, Write and Edit Market to Surge to... Source: Bcc Research

Apr 6, 2026 @ 5:00 PM Idiopathic Membranous Nephropathy Market is Predic... Source: Delveinsight

Mar 25, 2026 @ 8:02 PM Where Will Vertex Pharmaceuticals Be in 1 Year? Source: Prosper Junior Bakiny

Mar 24, 2026 @ 3:05 PM Anti-Aging Protein Research Takes a Step Forward w... Source: Equity-Insider.Com

Financials
	TTM	Q4 2025	FY 2025
Basic EPS	$15.46	$4.69	$15.46
Diluted EPS	$15.32	$4.64	$15.32
Revenue	$12B	$3.19B	$12B
Gross Profit	$10.35B	$2.72B	$10.35B
Net Income / Loss	$3.95B	$1.19B	$3.95B
Operating Income / Loss	$4.17B	$1.21B	$4.17B
Cost of Revenue	$1.65B	$466M	$1.65B
Net Cash Flow	$515.6M	$140M	$515.6M
PE Ratio	28.50

Splits
Aug 24, 2000	2:1